Tbi-1301
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients
University Health Network, TorontoCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide University Health Network, Toronto | Phase 1 | CC |
Fludarabine University Health Network, Toronto | Phase 1 | CC |
Same molecule, other indications
Tbi-1301 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →